Laidlaw analyst Yale Jen weighed in with a favorable report on Repros Therapeutics Inc (NASDAQ:RPRX), following a meeting with RPRX management, which left her more confident that the outcome of the upcoming AdCom meeting would be positive and Enclomiphene (formerly Androxal) could be approved by the FDA.

Jen wrote, “We believe there is a high likelihood that the outcome from the Nov. 3 rd AdCom meeting could be positive. Our bullish thesis is based on: 1) consistently robust clinical data; 2) increased awareness and off-label use of clomiphene for patients who want to preserve fertility; 3) Enclomiphene is the only near-term viable alternative therapy in front of the FDA; and 4) substantial unmet needs exist for large number (>80%) of hypogonadism (HG) patients. We also believe it would be important to have favorable decisions with substantially large margin by panel votes to demonstrate support from medical communities to the FDA.”

The analyst continued, “RPRX recently has changed the proposed product label to a more restricted one. It changed from all 2nd HG to 2nd HG with BMI>21 and <60 year old who exhibits endocrine society defined 2nd HG signs and intends to preserve fertility. We believe this could create some good will on the part of the FDA given the objective of agency’s Sep. 2014 AdCom meeting was to curtail very broad use (possibly abuse) of TRT.”

Jen reiterated a Buy rating on RPRX with a $28 price target, which represents a potential upside of nearly 280% from where the stock is currently trading.


Out of the 5 analysts polled by TipRanks, 4 rate Repros Therapeutics stock a Buy, while 1 rates the stock a Hold. With a return potential of 280.7%, the stock’s consensus target price stands at $28.40.